Tag Archives: BI 456906

Boehringer Ingelheim reports Phase III SYNCHRONIZE-2 data showing survodutide weight reduction and glycemic improvements in adults with obesity and type 2 diabetes

The 76-week trial met its co-primary endpoints, with up to 13.1% average weight loss using the efficacy estimand and improvements in HbA1c, waist circumference and insulin sensitivity. IN BRIEFKEY TAKEAWAYSFAQs Boehringer Ingelheim reported positive Phase III SYNCHRONIZE-2 results for investigational … Read the full press release →